Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.

Slides:

Advertisements

Similar presentations

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

Advertisements

Silent Ischemia STABLE CAD

Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.

Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quality of Life After PCI vs CABG Among Patients.

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic Value of Cardiac Computed Tomography.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The Effect of Coronary Revascularization on Regional Myocardial.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic implications of atrial fibrillation in.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Drug-Eluting Versus Bare-Metal Stents During PCI.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prevalence and Clinical Implications of Newly Revealed,

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic Value of Multislice Computed Tomography.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease by Stephan D. Fihn, Julius.

American College of Cardiology/American Heart Association Expert Consensus Document on Electron- Beam Computed Tomography for the Diagnosis and Prognosis.

From: Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The Elusive Role of Myocardial Perfusion Imaging in.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

American Journal of Cardiology

Volume 385, Issue 9985, Pages (June 2015)

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Fully automated analysis of attenuation corrected SPECT.

Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Kaplan-Meier survival for adult heart transplants performed between January 1982 and June 2006 by era. All comparisons are significant at p < (Reproduced.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.

Copyright © 2009 American Medical Association. All rights reserved.

Richard E. Kerber, M.D., Roger A. Miller, M.D., Sakib M. Najjar, M.D.

Circ Cardiovasc Interv

by Alexander Kulik, Ian G. Burwash, Varun Kapila, Thierry G

Circ Cardiovasc Interv

Circ Cardiovasc Imaging

Iatrogenic Adverse Events in the Coronary Care Unit

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

by Alexander Leaf, Christine M

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Patricia A. Ganz, MD The American Journal of Medicine

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Puja Gaur, MD, Tsuyoshi Kaneko, MD, Siobhan McGurk, BS, James D

Bjarne L. Nørgaard et al. JACC 2018;72:

Patricia A. Ganz, MD The American Journal of Medicine

The Impact of Peripheral Vascular Disease on Long-Term Survival After Coronary Artery Bypass Graft Surgery Danny Chu, MD, Faisal G. Bakaeen, MD, Xing.

Clinical factors associated with long-term mortality following vascular surgery: Outcomes from The Coronary Artery Revascularization Prophylaxis (CARP)

Left internal thoracic artery−radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective.

Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT Coronary microvascular.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Volume 14, Issue 12, Pages (December 2017)

Volume 385, Issue 9985, Pages (June 2015)

Volume 81, Issue 2, Pages (January 2012)

Predicting long-term functional results after myocardial revascularization in ischemic cardiomyopathy Giovanni Battista Luciani, MD, Giuseppe Montalbano,

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Complete Revascularization of the Three-Vessel Territories Using a Left Internal Thoracic Artery Composite Graft Ho Young Hwang, MD, PhD, Hong Chul Oh,

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Coronary revascularization induces a shift from cardiac toward noncardiac mortality without improving survival in vascular surgery patients Klaas H.J.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Presentation transcript:

Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography by Rory Hachamovitch, Sean W. Hayes, John D. Friedman, Ishac Cohen, and Daniel S. Berman Circulation Volume 107(23):2900-2907 June 17, 2003 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Unadjusted Kaplan-Meier survival in patients undergoing revascularization vs medical therapy (Medical Rx). Figure 1. Unadjusted Kaplan-Meier survival in patients undergoing revascularization vs medical therapy (Medical Rx). Rory Hachamovitch et al. Circulation. 2003;107:2900-2907 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Observed cardiac death rates over the follow-up period in patients undergoing revascularization (Revasc) vs medical therapy (Medical Rx) as a function of the amount of inducible ischemia. Figure 2. Observed cardiac death rates over the follow-up period in patients undergoing revascularization (Revasc) vs medical therapy (Medical Rx) as a function of the amount of inducible ischemia. Increase in cardiac death frequency as a function of inducible ischemia, P<0.0001. Rory Hachamovitch et al. Circulation. 2003;107:2900-2907 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Likelihood of referral to revascularization as a function of % myocardium ischemic based on logistic regression analysis. Figure 3. Likelihood of referral to revascularization as a function of % myocardium ischemic based on logistic regression analysis. TAP indicates typical angina; Atyp, atypical angina pectoris; and Asx, asymptomatic. Rory Hachamovitch et al. Circulation. 2003;107:2900-2907 Copyright © American Heart Association, Inc. All rights reserved.

Figure 4. Log hazard ratio for revascularization (Revasc) vs medical therapy (Medical Rx) as a function of % myocardium ischemic based on final Cox proportional hazards model. Figure 4. Log hazard ratio for revascularization (Revasc) vs medical therapy (Medical Rx) as a function of % myocardium ischemic based on final Cox proportional hazards model. Model, P<0.0001; interaction, P=0.0305. Rory Hachamovitch et al. Circulation. 2003;107:2900-2907 Copyright © American Heart Association, Inc. All rights reserved.